Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gemfibrozil + red yeast rice is a combination of the fibric acid derivative gemfibrozil and the dietary supplement red yeast rice (specifically the LipoCol Forte brand). Gemfibrozil functions as a PPAR-alpha agonist, primarily used to lower serum triglycerides and increase HDL cholesterol. Red yeast rice is a fermented product of Monascus purpureus that contains monacolin K, which is chemically identical to the statin lovastatin and acts as an HMG-CoA reductase inhibitor to lower LDL cholesterol. This specific combination was the subject of a Phase 1 clinical pharmacokinetic study conducted by National Taiwan University Hospital to evaluate the safety and potential drug-drug interactions between the two agents, as concomitant use of fibrates and statins is known to increase the risk of myopathy and rhabdomyolysis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gemfibrozil + red yeast rice.